The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Plasticity in designing PROTACs for selective and potent degradation of HDAC6
Abstract
HDAC6 (histone deacetylase 6) catalyses the deacetylation of non-histone substrates, and plays important roles in cell migration, protein degradation and other cellular processes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CRBN-based PROTACs recruiting a pan-HDAC inhibitor AB3 or a HDAC6 selective binder nexturastat A resulted in specific degradation of HDAC6.”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [137]
Citations
Cites
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Erasers of Histone Acetylation: The Histone Deacetylase EnzymesPreprint
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 2,105
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Targeted protein degradation by PROTACs
Neklesa, T. K., Winkler, J. D., & Crews, C. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.027 · Cited by 599
Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR
Boettcher, M., & McManus, M. T. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.028 · Cited by 539
HDAC6: a key regulator of cytoskeleton, cell migration and cell–cell interactions
Valenzuela-Fernández, A., Cabrero, J. R., Serrador, J. M., & Sánchez‐Madrid, F. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.04.003 · Cited by 510
Histone deacetylases and cancer
Barneda‐Zahonero, B., & Parra, M. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.07.003 · Cited by 449
Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes
Li, Y., Shin, D., & Kwon, S. H. (2012) · FEBS Journal · doi:10.1111/febs.12079 · Cited by 351
Structural insights into HDAC6 tubulin deacetylation and its selective inhibition
Miyake, Y., Keusch, J. J., Wang, L., Saito, M., Hess, D., Wang, X., Melancon, B. J., Helquist, P., Gut, H., & Matthias, P. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2140 · Cited by 315
Sun, Y., Zhao, X., Ding, N., Gao, H., Wu, Y., Yang, Y., Zhao, M., Hwang, J., Song, Y., Liu, W., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0055-1 · Cited by 295
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–117 of 117
PROTACS- targeted protein degradation as a path to precision cancer therapeutics
Gatley, H. R., Fisher, P. B., & Das, S. K. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.08.001
Zhang, X., Chen, Q., Lei, C., Jin, D. L., Liu, H. D., Wang, Y., zhao, C., Zhi, L., & Liu, X. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00281a
Linker attachment points: “finishing touch” in PROTAC design
jiang, Q., Shi, H.-S., Zhao, C.-S., Wang, Z.-Y., Yu, M.-M., Zhang, X.-Y., & Liu, C.-J. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00346j
Enzyme−Targeted Therapeutics for Neurological Disorders
Massignan, L., Lokesh, K., Ziadat, S., Uehling, D., Weaver, D. F., & Reed, M. A. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01274
BindingDB (2026) · UC San Diego · doi:10.7270/q29s1ww4
BindingDB Entry 50018659: Developments of CRBN-based PROTACs as potential therapeutic agents.
BindingDB (2024) · UC San Diego · doi:10.7270/q27948wc
BindingDB Entry 50013121: Discovery of a PROTAC targeting ALK with in vivo activity.
BindingDB (2022) · UC San Diego · doi:10.7270/q25h7m0f
BindingDB Entry 50021665: The application of PROTAC in HDAC.
BindingDB (2025) · UC San Diego · doi:10.7270/q2474gjr
BindingDB Entry 50021137: HDAC-targeting epigenetic modulators for cancer immunotherapy.
BindingDB (2025) · UC San Diego · doi:10.7270/q2rx9hnw
BindingDB Entry 50018797: A bibliometric analysis of PROTAC from 2001 to 2021.
BindingDB (2024) · UC San Diego · doi:10.7270/q28p64s7
BindingDB (2024) · UC San Diego · doi:10.7270/q2x352pq
BindingDB (2023) · UC San Diego · doi:10.7270/q25t3qmb
Metadata
- Authors
- Yang, H., Lv, W., He, M., Deng, H., Li, H., Wu, W., & Rao, Y.
- Affiliations
- Tsinghua University (CN)
- Center for Life Sciences (CN)
- Corresponding author
- Wu, Wei
- Rao, Yu
- Venue
- Chemical Communications
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2019
- Volume
- 55
- Issue
- 98
- Pages
- 14848-14851
- ISSN
- 1359-7345 (ISSN-L)
- 1364-548X
- OpenAlex
- W2990849042
- Cited by
- 108
- References
- 24
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 11 · 2023: 17 · 2022: 23 · 2021: 14 · 2020: 18
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Communications (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81573277, 81622042, 81672950, 81773567)
- National Major Science and Technology Projects of China (SQ2017ZX095003)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, HDAC6, protein degradation, cereblon, pomalidomide, aliphatic chains, degron
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
